marked.bio

mutant-selective PI3Kα inhibitor · small molecule

RLY-2608

1 active trials, targeting mutant PI3Kα. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
PIK3CA activating mutation 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of RLY-2608.

  1. Relay Therapeutics 1

Trials

1 of 1 trials shown

  1. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    Recruiting Phase 1 Relay Therapeutics Started 2021Primary completion 2027-04 NCT05216432

    RLY-2608fulvestrant FDA EUpalbociclib FDA EUribociclibPF-07220060 100mgPF-07220060 300 mg

    One or more documented primary oncogenic PIK3CA mutation(s) in blood and/or tumor per local assessment

    PIK3CA activating mutationPIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer